Oxford BioDynamics Announces Successful Pfizer Study on EpiSwitch Biomarkers
Why we think this is neutral
This RNS announcement provides a general update on the successful use of Oxford BioDynamics' EpiSwitch biomarkers in a Pfizer study, which does not fall into any of the mandatory news categories. The announcement highlights the potential of the EpiSwitch technology in cancer detection and monitoring, but does not contain any specific financial or operational updates.
Key Points
- Pfizer publishes data on successful use of EpiSwitch biomarkers in evaluating tumour status and treatment outcomes from the JAVELIN Bladder 100 Trial
- Results demonstrate EpiSwitch blood-based biomarkers can effectively determine whether a tumour has high or low immune activity, an important factor in cancer treatment decisions
- EpiSwitch technology has the potential to revolutionise cancer detection and monitoring across various types of cancer
Summary
Oxford BioDynamics (OBD) has announced that Pfizer has published data on the successful use of the company's EpiSwitch blood-based biomarkers in the evaluation of tumour status and treatment outcomes of 496 patients from the JAVELIN Bladder 100 Trial. The results strongly support the use of EpiSwitch as an effective liquid biopsy method to evaluate and monitor the state of tissues and tumors in cancer patients. This adds to the growing evidence of the quality and efficacy of EpiSwitch biomarker products, which have already been translated into clinical practice.